Geode Capital Management
MBRX icon

Geode Capital Management’s Moleculin Biotech MBRX Stock Holding History

Geode Capital Management’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$74K Buy
32,329
+17,191
+114% +$56.9K ﹤0.01% 4214
2025
Q4 		$50.1K Buy
15,138
+6,810
+82% +$63.5K ﹤0.01% 4231
2025
Q3 		$110K Buy
8,328
+7,227
+656% +$97.6K ﹤0.01% 4105
2025
Q2 		$8.31K Buy
1,101
+59
+6% +$1.21K ﹤0.01% 4423
2025
Q1 		$25.4K Buy
1,042
+161
+18% +$5.41K ﹤0.01% 4307
2024
Q4 		$37.5K Buy
881
+8
+0.9% +$485 ﹤0.01% 4287
2024
Q3 		$62K Buy
873
+83
+11% +$5.98K ﹤0.01% 4220
2024
Q2 		$69K Buy
790
+126
+19% +$14.6K ﹤0.01% 4218
2024
Q1 		$98.2K Buy
664
+6
+0.9% +$1.28K ﹤0.01% 4163
2023
Q4 		$212K Hold
658
– – ﹤0.01% 3922
2023
Q3 		$105K Buy
658
+1
+0.2% +$207 ﹤0.01% 4232
2023
Q2 		$143K Hold
657
– – ﹤0.01% 4197
2023
Q1 		$237K Hold
657
– – ﹤0.01% 3957
2022
Q4 		$261K Sell
657
-2
-0.3% -$844 ﹤0.01% 3949
2022
Q3 		$261K Hold
659
– – ﹤0.01% 4051
2022
Q2 		$358K Buy
659
+4
+0.6% +$2.33K ﹤0.01% 3942
2022
Q1 		$437K Hold
655
– – ﹤0.01% 4004
2021
Q4 		$456K Hold
655
– – ﹤0.01% 4105
2021
Q3 		$736K Buy
655
+21
+3% +$24.5K ﹤0.01% 3839
2021
Q2 		$871K Buy
634
+168
+36% +$229K ﹤0.01% 3679
2021
Q1 		$713K Buy
466
+335
+256% +$614K ﹤0.01% 3688
2020
Q4 		$234K Buy
131
+25
+24% +$44.4K ﹤0.01% 3837
2020
Q3 		$193K Buy
106
+5
+5% +$10.6K ﹤0.01% 3732
2020
Q2 		$219K Buy
101
+45
+80% +$107K ﹤0.01% 3639
2020
Q1 		$77K Hold
56
– – ﹤0.01% 3839
2019
Q4 		$115K Hold
56
– – ﹤0.01% 3956
2019
Q3 		$140K Hold
56
– – ﹤0.01% 3879
2019
Q2 		$158K Hold
56
– – ﹤0.01% 3850
2019
Q1 		$102K Hold
56
– – ﹤0.01% 3892
2018
Q4 		$131K Hold
56
– – ﹤0.01% 3806
2018
Q3 		$202K Hold
56
– – ﹤0.01% 3766
2018
Q2 		$226K Buy
56
+18
+47% +$73.7K ﹤0.01% 3685
2018
Q1 		$154K Hold
38
– – ﹤0.01% 3755
2017
Q4 		$159K Buy
38
+12
+46% +$51.9K ﹤0.01% 3728
2017
Q3 		$140K Hold
26
– – ﹤0.01% 3746
2017
Q2 		$110K Buy
+26
New +$56.6K ﹤0.01% 3826

Other funds holding MBRX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM
PWPS
Pinnacle Wealth Planning Services Mansfield, Ohio $968M AUM 19.1% 1-Year Est. Return

Geode Capital Management's MBRX Position: Q1 2026 in Review

Geode Capital Management increased its Moleculin Biotech (MBRX) stake by 114% in Q1 2026, buying an estimated $56.9K and bringing the position to 32,329 shares worth $74K. The position accounts for ﹤0.01% of the portfolio, ranked #4214.

Geode Capital Management first reported a position in MBRX in Q2 2017 and has held it in 36 quarters since. The position peaked at $871K in Q2 2021. 20 funds tracked by Wall St. Rank hold MBRX as of Q1 2026.

  • Geode Capital Management held 32,329 shares of Moleculin Biotech worth $74K as of Q1 2026.
  • Geode Capital Management bought 17,191 Moleculin Biotech shares in Q1 2026, an estimated $56.9K.
  • Moleculin Biotech made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4214 holding.
  • Geode Capital Management first reported a position in Moleculin Biotech in Q2 2017 and has held it in 36 quarters since.
  • Geode Capital Management's Moleculin Biotech position peaked at $871K in Q2 2021.
  • 20 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.